Skip to main content
Caplight Logo









Endogena Therapeutics

Endogena Therapeutics

Private
ZurichHealthcare & Life Scienceshttps://endogena.com/

Last Round

Series A

Extension

Dec 13, 2021

Total Funding Raised

$29M

Company Overview

Endogena Therapeutics is a clinical-stage biotech company that discovers and develops first-in-class endogenous regenerative medicines to repair and regenerate tissues and organs, with a focus on degenerative diseases of the eye.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Medical AI

Business Model

B2B2C

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

regenerative medicineRetinitis PigmentosaRPstem cell therapysmall molecule therapeuticsendogenous stem cell activationgene-independent therapyretinal disease treatmentGeographic Atrophyvision restorationAge-related Macular DegenerationAMDphotoreceptor regenerationtissue regenerationclinical-stage biotechnologyOrphan Drug DesignationAI drug discovery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Endogena Therapeutics Comparables

Compare Endogena Therapeutics with similar companies based on industry and business-model similarity.

Endogena Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Centenara Labs
94%
jCyte, Inc.
87%
Nacuity Pharmaceuticals, Inc.
83%

Endogena Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionDec 13, 2021
Series AJan 26, 2021

Endogena Therapeutics Investors

Notable investors and investment history

Endogena Therapeutics investors
InvestorRounds
DEFTA PartnersSeries A Extension, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 7, 2025

    Monthly visitors increased 41% MoM.

  • Dec 13, 2021

    $21M round led by Centenara Labs.

Endogena Therapeutics Filings

Explore SEC and related filing metadata, where available.

Endogena Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Endogena Therapeutics's valuation, stock price, and market status.

Is Endogena Therapeutics a public or private company?

Endogena Therapeutics is a private company.

What is the current stock price of Endogena Therapeutics?

Endogena Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is Endogena Therapeutics worth (valuation)?

Valuation information for Endogena Therapeutics is not publicly available.

Can I buy Endogena Therapeutics stock?

Endogena Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Endogena Therapeutics's last funding round?

Endogena Therapeutics's most recent funding round was Series A Extension on December 13, 2021.

Who are the main investors in Endogena Therapeutics?

Key investors in Endogena Therapeutics include DEFTA Partners.

Will Endogena Therapeutics IPO soon?

No public IPO plans have been announced for Endogena Therapeutics.

How can I track Endogena Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Endogena Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersZurich
Employee Range2
Year Founded2016
Last FundingDec 13, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?